Commentary on Development of the Prognostic Factors Concept in Chronic Lymphocytic Leukaemia: The Route from Prognostic Factors to Therapy Response Predictors

Česká verzia

Authors: T. Balhárek ¹; M. Barthová ¹; P. Szépe ¹; J. Marcinek ¹; T. Burjanivová ²; L. Plank ¹
Authors place of work: Ústav patologickej anatómie a Konzultačné centrum bioptickej diagnostiky ochorení krvotvorby JLF UK a MFN, Martin, Slovenská republika ¹; Ústav molekulovej biológie JLF UK, Vrútky, Slovenská republika ²
Published in the journal: Klin Onkol 2009; 22(6): 254-263
Category: Reviews

Summary

Chronic lymphocytic leukaemia (CLL) is a lymphoproliferative disorder with variable clinical course. Determination of disease prognosis is based on the identification of different prognostic factors. The concept of CLL prognostic factors is still developing and has undergone several fundamental changes. Traditional (old) prognostic factors and staging systems are useful in describing the extent of the disease at any given moment, in determining clinical progression and in the identification of patients who need to start treatment. However, traditional prognostic factors are not sufficient for predicting a long‑term prognosis because they are not able to identify potentially aggressive forms of CLL in the early stages. Nevertheless, clinical staging systems maintain their importance and in contrast to other traditional factors also their independent prognostic role. Otherwise, traditional prognostic factors play the role of disease activity descriptors rather than the role of actual prognostic factors. CLL risk profile determination is based on the identification of so‑ called new prognostic factors, the most relevant of which are chromosomal aberrations, TP53 gene mutations, mutational status of IgV_H genes, ZAP‑ 70 and CD38 expression. These factors are able to predict the prognosis already at the time of the initial diagnosis. In contrast to previous ideas, they are not incorporated into recommendations regarding indications for treatment. This is due to the risks associated with early treatment and the lack of data validated in prospective clinical trials demonstrating the justifiability of such procedure. In patients being treated, new prognostic factors may be useful for predicting the response to the therapy and some of them may directly influence the choice of treatment regime. New CLL treatment modalities have also raised the question of their influence on the prognostic and predictive power of new prognostic factors.

Key words:
chronic lymphocytic leukemia – treatment outcome – prognosis – prognostic factors

Zdroje

1. Chiorazzi N, Rai KR, Ferrarini M. Mechanisms of disease: Chronic lymphocytic leukemia. N Eng J Med 2005; 352(8): 804– 815.

2. Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194(11): 1639– 1647.

3. Moreno C, Montserrat E. New markers in chronic lymphocytic leukemia. Blood Reviews 2008; 22(4): 211– 219.

4. Montserrat E. Find your way around prognostic factors in CLL. Abstract book: Looking to the future: How evidence changes clinical practice – Expert Investigator Forum. Budapest 2008; 22– 23.

5. Mayer J, Schwarz J, Doubek M et al. Co nám v každodenní praxi skutečne říkají tzv. moderní prognostické faktory u chronické lymfatické leukemie? Transfuze a Hematologie Dnes 2007; 3: 106– 116.

6. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219– 234.

7. Binet JL, Lepoprier M, Dighiero G et al. A clinical staging system of chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855– 864.

8. Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: Where to now? Haematol J 2002; 3: 7– 9.

9. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J Clin Pathol 1989; 42: 567– 584.

10. Müller‑ Hermelink HK, Montserrat E, Catovsky D et al. Chronic lymphocytic leukaemia/ small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL et al (eds.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, 2008; 180– 182.

11. Damle RN, Wasil T, Fais, F et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840– 1847.

12. Hamblin TJ, Davis Z, Gardiner A et al. Unmutated IgV_H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848– 1854.

13. Thorsélius M, Kröber A, Murray F et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3– 21– using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006; 107(7): 2889– 2894.

14. Mraz M, Pospisilova S, Malinova K et al. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 2009; 50(3): 506– 509.

15. Mainou‑ Fowler T, Dignum HM, Proctor SJ et al. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B‑ CLL). Leuk Lymphoma 2004; 45(3): 455– 462.

16. Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99(3): 1023– 1029.

17. Kröber A, Seiler T, Benner A et al. VH mutation status, CD38 expression level, genomic aberrations and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410– 1416.

18. Ghia P, Guida G, Stella S et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262– 1269.

19. Crespo M, Bosch F, Villamor N et al. ZAP‑ 70 expression as a surrogate for immunoglobulin‑variable‑ region mutations in chronic lymphocytic leukemia. N Eng J Med 2003; 348(18): 1764– 1775.

20. Orchard JA, Ibbotson RE, Davis Z et al. ZAP‑ 70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105– 111.

21. Wiestner A, Rosenwald A, Barry TS et al. ZAP‑ 70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 2003; 101(12): 4944– 4951.

22. Rassenti LZ, Huynh L, Toy TL. ZAP‑ 70 compared with immunoglobulin heavy‑chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Eng J Med 2004; 351(9): 893– 901.

23. Villamor N, Crespo M, Bosch F et al. ZAP‑ 70 expression remains stable during the course of chronic lymphocytic leukemia. Leuk Lymphoma 2005; 49 (Suppl 1): S43.

24. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med 2000; 343(26): 1910– 1916.

25. Castoldi G, Cuneo A. Cytogenetic and molecular cytogenetic features in chronic lymphocytic leukemia. Haematologica 2003; 88 (Suppl 17): 9– 13.

26. Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine pluscyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370(9583): 230– 239.

27. Thornton PD, Gruszka‑ Westwood AM, Hamoudi RA et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 2004; 5: 47– 54.

28. Zenz T, Kröber A, Scherer K et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long‑term follow‑up. Blood 2008; 112(8): 3322– 3329.

29. Rossi D, Cerri M, Deambrogi C et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15(3): 995– 1004.

30. Dicker F, Herholz H, Schnittger S et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23(1): 117– 124.

31. Döhner H, Fischer K, Bentz M. p53 gene deletions predicts for poor survival and non‑response to therapy with purine analogues in chronic B‑ cell leukemias. Blood 1995; 85: 1580– 1589.

32. Grever MR, Lucas DM, Dewald GW et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25(7): 799– 804.

33. Byrd JC, Smith L, Hackbarth ML et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to Rituximab. Cancer Res 2003; 63: 36– 38.

34. Zenz T, Häbe S, Denzel T et al. Detailed analysis of p53 pathway defects in fludarabine‑ refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53– p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114(13): 2589– 2597.

35. Malcikova J, Smardova J, Rocnova L et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. Blood 2009.

36. Döhner H, Stilgenbauer S, Jemes MR et al. 11q deletions identify a new subset of B‑ cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89: 2516– 2522.

37. Austen B, Powell JE, Alvi A et al. Mutations in the ATM gene lead to impaired overall and treatment‑free survival that is independent of IGV_H mutation status in patients with B‑ CLL. Blood 2005; 106(9): 3175– 3182.

38. Cejkova S, Rocnova L, Potesil D et al. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. Europ J Haematol 2008; 82: 133– 142.

39. Stilgenbauer S, Lichter P, Döhner H. Genetic features of B‑ cell chronic lymphocytic leukemia. Reviews in Clin Experiment Hemat 2000; 4: 48– 72.

40. Brejcha M, Mayer J, Klodová D et al. Klonální evoluce u chronické lymfocytární leukemie. Transfuze a Hematologie Dnes 2009; 2: 103– 106.

41. Stilgenbauer S, Sander S, Billinger L et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high‑risk genomic aberrations associated with unmutated VH, resistance to therapy and short survival. Haematologica 2007; 92(9): 1242– 1245.

42. Matutes E, Oscier DG, Garcia‑ Marco J et al. Trisomy 12 defines group of CLL with atypical morphology. Correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996; 92: 382– 388.

43. Buhl AM, Jurlander J, Geisler CH et al. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Europ J Haematol 2006; 76(6): 455– 464.

44. Stilgenbauer S, Bullinger L, Lichter P et al. Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993– 1007.

45. Rassenti LZ, Jain S, Keating MJ et al. Relative value of ZAP‑ 70, CD38 and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112(5): 1923– 1930.

46. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood 2008; 111(12): 5446– 5456.

47. Montserrat E. New prognostic markers in CLL. Hematology – ASH Education Program Book 2006; 279– 284.

48. Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278– 3281.

49. Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109(2): 405– 411.

50. Hauswirth AW, Jäger U. Impact of genetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia. Haematologica 2008; 93(1): 14– 19.

51. Del Poeta G, Del Principe MI, Consalvo MAI et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP‑ 70– negative chronic lymphocytic leukemia. Cancer 2005; 104(12): 2743– 2752.

52. Byrd JC, Gribben JG, Peterson BL et al. Select high‑risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk‑adapted therapy. J Clin Oncol 2006; 24(3): 437– 443.

53. Del Poeta G, Del Principe MI, Buccisano F et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B‑ cell chronic lymphocytic leukemia. Cancer 2008; 112(1): 119– 128.

54. Lin KI, Tam CS, Keating MJ et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009; 113(14): 3168– 3171.

55. Keating MJ, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 1– 8.

56. Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12– 17.

57. Papajík T, Raida L, Faber E et al. Chronická B‑lymfocytární leukemie. Část V. Transplantace krvetvorných buněk. Transfuze a Hematologie Dnes 2007; 3: 100– 105.

58. Caballero D, Garcia‑ Marco JA, Martino R et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B‑ cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy‑chain gene and chromosomal abnormalities. Clin Cancer Res 2005; 11(21): 7757– 7763.

59. Khouri IF, Saliba RM, Keating MJ. ZAP‑ 70 status may not predict outcome after non‑myeloablative allogeneic transplantation (NMT) in patients with chronic lymphocytic leukemia (CLL) who failed conventional chemotherapy. Blood 2006; 106 (Suppl 1): 577a.

60. Brown JR, Kim HT, Li S et al. Predictors of improved progression‑free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006; 12(10): 1056– 1064.

61. Bosch F, Ferrer A, Villamor N et al. Fludarabine, Cyclophosphamide and Mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication. Clin Cancer Res 2008; 14(1): 155– 161.

62. Tam CS, O’Brien S, Wierda W et al. Long‑term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975– 980.

63. Rawstron AC, Villamor N, Ritgen M et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia. Leukemia 2007; 21(5): 956– 964.

64. Bezdíčková L, Špaček M, Peková S et al. Minimální reziduální nemoc u chronické lymfocytární leukemie: metody stanovení a klinický význam. Transfuze a Hematologie Dnes 2008; 3: 124– 130.